NTV Asset Management LLC Sells 10,644 Shares of Pfizer Inc. $PFE

Key Points

• NTV Asset Management LLC reduced its stake in Pfizer Inc. by 18.6%, selling 10,644 shares during the second quarter, which brought their total holdings to 46,591 shares worth approximately $1,129,000.
• Several other institutional investors increased their holdings in Pfizer, with Bourne Lent Asset Management Inc. significantly boosting its stake by 90.8% in the same quarter.
• Pfizer reported a quarterly EPS of $0.78, exceeding expectations, with a net revenue of $14.65 billion, reflecting a year-over-year increase of 10.3%.

NTV Asset Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 18.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,591 shares of the biopharmaceutical company's stock after selling 10,644 shares during the quarter. NTV Asset Management LLC's holdings in Pfizer were worth $1,129,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bessemer Group Inc. lifted its holdings in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK increased its stake in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Pfizer in the first quarter valued at approximately $8,283,000. Westbourne Investments Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. increased its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock opened at $27.37 on Friday. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $24.67 and a 200-day moving average of $24.15.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Saturday, September 27th. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. UBS Group reaffirmed a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Finally, Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.